Biomarin Pharmaceutical (BMRN) Short term Debt (2016 - 2024)
Historic Short term Debt for Biomarin Pharmaceutical (BMRN) over the last 15 years, with Q2 2024 value amounting to $494.8 million.
- Biomarin Pharmaceutical's Short term Debt changed N/A to $494.8 million in Q2 2024 from the same period last year, while for Jun 2024 it was $494.8 million, marking a year-over-year change of. This contributed to the annual value of $493.9 million for FY2023, which is 300126.84% up from last year.
- As of Q2 2024, Biomarin Pharmaceutical's Short term Debt stood at $494.8 million.
- Biomarin Pharmaceutical's 5-year Short term Debt high stood at $494.8 million for Q2 2024, and its period low was $15.9 million during Q4 2022.
- Its 5-year average for Short term Debt is $225.6 million, with a median of $64.0 million in 2022.
- Its Short term Debt has fluctuated over the past 5 years, first skyrocketed by 364290.0% in 2020, then crashed by 9158.11% in 2021.
- Over the past 5 years, Biomarin Pharmaceutical's Short term Debt (Quarter) stood at $374.3 million in 2020, then tumbled by 87.11% to $48.2 million in 2021, then plummeted by 66.98% to $15.9 million in 2022, then surged by 3001.27% to $493.9 million in 2023, then increased by 0.19% to $494.8 million in 2024.
- Its Short term Debt stands at $494.8 million for Q2 2024, versus $494.4 million for Q1 2024 and $493.9 million for Q4 2023.